By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Phathom Pharmaceuticals, Inc. the people running the company have only been selling lately: one insider unloaded about $7,079 of stock over 12 months, with no open-market purchases.
That's worth context: executives sell for plenty of routine reasons, from scheduled trading plans to tax bills. Buying is the rarer, more telling signal.
162 investment managers listed PHAT in their latest 13F filings (Q2 2026); funds were split between buying and selling. Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 2 of the last 7 full quarters.
Are insiders buying or selling PHAT stock?
In the last 12 months Phathom Pharmaceuticals, Inc. insiders made open-market purchases worth about $0 and sales worth about $7,079. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in PHAT?
The most recent open-market insider trade in PHAT was filed on 2025-11-05.
How many institutions own PHAT?
162 investment managers reported holding PHAT in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded PHAT?
No congressional trades in PHAT were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).